Where does Klaus Veitinger work?

Klaus Veitinger is Venture Partner at OrbiMed and Founder at Alpheus Medical and Founder at Sparrow Pharma and Founder at Tricida.

What does Klaus Veitinger invest in?

Klaus Veitinger invests in Biotech.

What check size does Klaus Veitinger write?

Klaus Veitinger typically writes checks of $1M – $75M.

Klaus Veitinger

InvestorFounder

Venture Partner at OrbiMed · Board director at Alpheus Medical · Board director at Sparrow Pharma · Board director at Tricida

New York, New York

Writes $1M – $75M checks · typically $4M

FoundedAlpheus Medical Promentis Pharmaceuticals Sparrow Pharma Symbiomix Therapeutics Tricida

About

Klaus Veitinger joined OrbiMed in 2007 as a Venture Partner, focusing on venture investments in therapeutics, and has held board roles at various OrbiMed portfolio companies. He previously served as CEO of Schwarz Pharma Inc., overseeing its U.S. and Asia businesses through the sale of the Schwarz Group, and spent seven years as a Director of PhRMA. He holds a medical degree and Ph.D. from the University of Heidelberg and an M.B.A. from INSEAD.

Invests in

Biotech

Board director at Alpheus Medical

Intro paths

→

In turn, Klaus can intro founders to Alpheus Medical's investors below.

Alpheus Medical's investors · 3

Action Potential Venture Capital Ltd.Scotts Valley · since 2025 OrbiMedNew York · $1M – $75M checks · since 2025 SV Health InvestorsBoston · $1M – $20M checks

Co-founders at Alpheus Medical

Jeremy LingExecutive Officer

Steve WeinerExecutive Officer

Vijay AgarwalExecutive Officer, Director

William DavisExecutive Officer, Director

Board director at Sparrow Pharma

Intro paths

→

In turn, Klaus can intro founders to Sparrow Pharma's investors below.

Sparrow Pharma's investors · 4

OrbiMedNew York · $1M – $75M checks · since 2025 RA CapitalBoston RiverVest Venture PartnersSt. Louis · $500K – $3M checks · since 2025 US Venture PartnersMenlo Park · $500K – $10M checks

Co-founders at Sparrow Pharma

Robert JacksExecutive Officer, Director

David Aaron KatzExecutive Officer, Director

Board director at Tricida

Intro paths

→

In turn, Klaus can intro founders to Tricida's investors below.

Tricida's investors · 3

Avoro Capital AdvisorsNew York Longitude CapitalMenlo Park · $10M – $30M checks OrbiMedNew York · $1M – $75M checks · since 2016

Co-founders at Tricida

Gerrit KlaernerExecutive Officer, Director

Melissa MikschExecutive Officer

Experience

OrbiMedVenture Partnercurrent2007 — presentNew York, United States
Helicore BiopharmaExecutive Chairmancurrent2024 — present
Sparrow Pharmaceuticals, Inc.Chairman of the Boardcurrent2021 — present
Alpheus Medical, IncExecutive Chairmancurrent2020 — present
FDA - Brain Cancer Research RoundtableInvestor Representativecurrent2021 — present
Cure Rare DiseaseBoard Membercurrent2024 — present
Alliance for Cancer Gene TherapyBoard Membercurrent2020 — present
scPharmaceuticalsBoard Member2017 — 2025
Neurogastrx, Inc.Chairman of the Board2017 — 2025
Tricida, Inc.Chairman of the Board2013 — 2023South San Francisco, California, United States
Symbiomix Therapeutics, LLCCEO2014 — 2017
Intercept PharmaceuticalsBoard Member2012 — 2016
RELYPSA, INC.Vice Chairman of the Board2010 — 2015
Synageva BioPharma Corp.Board Member2007 — 2008
Schwarz Pharma Inc.CEO1998 — 2006
AnorMEDVice Chairman of the Board2006

Education

Heidelberg UniversityDoctor of Medicine (M.D.)1982 — 1988
INSEADMaster of Business Administration (MBA)1994
Heidelberg UniversityDoctor of Philosophy (PhD)1984 — 1991

Skills & more

CEOVenture CapitalPharmaceutical IndustryBiotechnologyLife SciencesStart upsPrivate EquityTurn Around ManagementClinical TrialsFDARegulatory AffairsClinical Development

+9 more

Due DiligenceBusiness StrategyBiopharmaceuticalsCommercializationResearch and Development (R&D)LicensingMergers & Acquisitions (M&A)Business DevelopmentDrug Development

From Klaus's professional profile.

Deals · 4

Alpheus MedicalBoard seat

via OrbiMed · filed Jul 2026 · $67M raise

Promentis PharmaceuticalsBoard seat

via OrbiMed · filed Dec 2019 · $6M raise

TricidaBoard seat

via OrbiMed · filed Jul 2016 · $55.5M raise

Symbiomix TherapeuticsBoard seat

via OrbiMed · filed May 2016 · $6M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at OrbiMed

Venture Partner at OrbiMed

Andrew P. Kanarek, CFA, CIPM

Network1

Daniel Coley

Associate at Cofounders Capital

Investors connected to Klaus in public investor directories — a warm-intro map.

Frequently asked questions

Where does Klaus Veitinger work?: Klaus Veitinger is Venture Partner at OrbiMed and Founder at Alpheus Medical and Founder at Sparrow Pharma and Founder at Tricida.
What does Klaus Veitinger invest in?: Klaus Veitinger invests in Biotech.
What check size does Klaus Veitinger write?: Klaus Veitinger typically writes checks of $1M – $75M.
What companies did Klaus Veitinger found?: Klaus Veitinger founded Alpheus Medical, Promentis Pharmaceuticals, Sparrow Pharma, Symbiomix Therapeutics, Tricida.